Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma

Inclusion Criteria: * Joined the study voluntarily and signed informed consent form; * Age 18-75；ECOG 0-2 * Esophageal squamous cell carcinoma , radical surgery ≤3 months,R0 resection. The operative incision healed well. * T3-4N0M0, T1-4N1-3M0 (according to AJCC2009) * No radiotherapy, chemotherapy or other treatments pre(post)surgery * PS ECOG 0-2 * Life expectancy of more than 3 months * Hemoglobin(Hb)≥9 g/dL • WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L • platelet count (Pt) ≥100x 109/L • Hepatic function: ALAT and ASAT \< 2.5 x ULN, TBIL\<1.5 x ULN • Renal function: creatinine \< 1.5 x ULN * No immuno-deficiency * Use of an effective contraceptive for adults to prevent pregnancy. Exclusion Criteria: * Complete esophageal obstruction after surgery, Esophageal perforation, Haematemesis * Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ, who survived with no evidence disease for over 3 years * Participation in other interventional clinical trials within 30 days * Pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives * Drug addiction, Alcoholism or AIDS * Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior * Unsuitable to be enrolled in the trial in the opinion of the investigators